Arrowhead Pharmaceuticals Inc (ARWR)

Days of sales outstanding (DSO)

		Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019
Receivables turnover		—	—	—	—	—	197.27	3.86	7.03	172.50	1,045.77	200.01	962.83	13.48	160.41	93.32	8.87	104.01	5.70	109.77	121.63
DSO	days	—	—	—	—	—	1.85	94.66	51.89	2.12	0.35	1.82	0.38	27.07	2.28	3.91	41.15	3.51	64.03	3.33	3.00

September 30, 2024 calculation

DSO = 365 ÷ Receivables turnover
= 365 ÷ —
= —

Based on the Days Sales Outstanding (DSO) data provided for Arrowhead Pharmaceuticals Inc over the past eight quarters, we can observe fluctuations in the collection period for accounts receivable.

In the most recent quarter, the DSO figure was not reported, suggesting a lack of transparency or changes in reporting practices. Prior to that, the DSO had shown a varying trend, with significant peaks and troughs. Notably, in March 2023 and September 2020, the DSO reached exceptionally high levels, indicating a delayed collection of sales revenues.

The DSO improved in the quarter ending June 2023, dropping to a relatively low level of 1.85 days, which is a positive sign of efficient accounts receivable management. However, this improvement was not sustained, as seen in subsequent quarters with DSO figures fluctuating.

Overall, Arrowhead Pharmaceuticals Inc's DSO trend indicates some inconsistency in collecting accounts receivable promptly. It would be beneficial for the company to focus on maintaining a more stable and lower DSO figure to optimize cash flow and working capital management.